Chimeric Antigen Receptor News and Research

RSS

Novel approach may prevent antibodies from triggering immune rejection of transplant cells

Researchers at UCSF have developed a novel, potentially life-saving approach that may prevent antibodies from triggering immune rejection of engineered therapeutic and transplant cells.

2 Jan 2023

Using synthetic gene circuits to better control the timing of immunotherapy

In two separate studies, researchers demonstrate how synthetic biology can be used to tackle a difficult issue in cancer immunotherapy: the way immunotherapy-related approaches focused on short-term killing of tumor cells may fail to eradicate tumors because growth of tumors happens on longer timescales.

16 Dec 2022

How human cell atlases provide the missing links between genes, diseases and therapies

A Nature Medicine journal perspective article describes the potential of cell atlases in shaping the future of medicine. Providing the missing link between genes and diseases, single-cell atlases make it possible to develop more precise and specific diagnostic tools by understanding the mechanisms of complex diseases.

12 Dec 2022

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

A patient with relapsed T cell leukemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).

12 Dec 2022

CAR T-cell therapy in colorectal cancer

Researchers assessed the efficacy of CAR T-cells in the immunotherapy of colorectal cancer.

21 Nov 2022

Researchers identify therapies for multiple myeloma patients whose cancer relapses after CAR-T

Mount Sinai and Memorial Sloan Kettering Cancer Center (MSK) researchers have identified therapies that can help patients with the blood cancer multiple myeloma who try an immunotherapy known as CAR-T only to find their cancer coming back afterwards.

4 Nov 2022

New approach to immunotherapy provokes a robust anti-tumor immune response in preclinical models

A new approach to cancer immunotherapy that uses one type of immune cell to kill another-;rather than directly attacking the cancer-;provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors in preclinical disease models, according to researchers at the Icahn School of Medicine at Mount Sinai in New York.

25 Oct 2022

Researchers streamline way to manufacture CAR T-cells in just 24 hours

Researchers at University Hospitals (UH) Seidman Cancer Center and a biotech start-up company have developed a streamlined way to manufacture CAR T-cells for immunotherapy treatment in just 24 hours – an improvement over the team's previous benchmark of eight days and commercial suppliers that typically take three weeks.

25 Oct 2022

CAR T-cell therapy produces impressive results in first clinical trial in patients with multiple myeloma

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.

29 Sep 2022

Study shows encouraging therapeutic options for patients with relapsed multiple myeloma

Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails.

1 Sep 2022

Powerful injectable gel provides hope for preventing glioblastoma relapse

Like the hardiest weed, glioblastoma almost always springs back -; usually within months after a patient's initial brain tumor is surgically removed.

8 Aug 2022

Higher doses of CAR-T therapy achieve better survival rates for young patients with hard-to-treat B-ALL

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.

8 Aug 2022

Efficacy of COVID mRNA vaccines among patients on CAR‐T‐lymphocyte therapy

Researchers evaluate the effectiveness of mRNA COVID-19 vaccines among patients receiving CAR‐T‐lymphocyte therapy.

27 Jul 2022

Improving the immune defenses against blood cancer

For patients with lymphoma, multiple myeloma, or certain types of leukemia, treatment with chimeric antigen receptor T cells (CAR T cells) is sometimes the last chance of overcoming the cancer.

22 Jul 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

Preclinical study unlocks the promise of CAR T-cell therapy for treatment of solid tumors

Scientists at St. Jude Children's Research Hospital identified a molecular mechanism that in a preclinical study unlocked the promise of CAR T–cell therapy for treatment of solid tumors.

22 Jun 2022

New screening tool could increase the number of tests on solid tumor sample by up to 50 times

A screening tool developed at the University of Strathclyde, UK, could increase the number of tests on a solid tumor sample by up to 50 times.

21 Jun 2022

Type I interferons play crucial role in fending off SARS-CoV-2

Researchers investigated whether individuals with breakthrough infections of COVID-19 pneumonia demonstrated normal antibody responses to vaccinations and whether they harbored type I interferon-neutralizing auto-antibodies.

16 Jun 2022

Researchers demonstrate the feasibility of pancreatic beta-cell, target-specific CAR-Treg treatment for T1D

Researchers have successfully treated type 1 diabetes in mice using pancreatic beta-cell, target-specific, chimeric antigen-receptor (CAR) regulatory T cells (Tregs), and demonstrated the feasibility of their approach to treat the human condition according to data being presented Monday, June 13 at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

13 Jun 2022